Literature DB >> 23445448

Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.

Matthew C O'Reilly1, Sarah A Scott, Kyle A Brown, Thomas H Oguin, Paul G Thomas, J Scott Daniels, Ryan Morrison, H Alex Brown, Craig W Lindsley.   

Abstract

An iterative parallel synthesis effort identified a PLD2 selective inhibitor, ML298 (PLD1 IC50 > 20000 nM, PLD2 IC50 = 355 nM) and a dual PLD1/2 inhibitor, ML299 (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM). SAR studies revealed that a small structural change (incorporation of a methyl group) increased PLD1 activity within this classically PLD2-preferring core and that the effect was enantiospecific. Both probes decreased invasive migration in U87-MG glioblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23445448      PMCID: PMC3632306          DOI: 10.1021/jm301782e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Overexpression of phospholipase D1 in human breast cancer tissues.

Authors:  D Y Noh; S J Ahn; R A Lee; I A Park; J H Kim; P G Suh; S H Ryu; K H Lee; J S Han
Journal:  Cancer Lett       Date:  2000-12-20       Impact factor: 8.679

Review 2.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

3.  The clinical significance of halopemide, a dopamine-blocker related to the butyrophenones.

Authors:  H De Cuyper; H M van Praag; D Verstraeten
Journal:  Neuropsychobiology       Date:  1984       Impact factor: 2.328

4.  Optimization of halopemide for phospholipase D2 inhibition.

Authors:  Lauren Monovich; Benjamin Mugrage; Elizabeth Quadros; Karen Toscano; Ruben Tommasi; Stacey LaVoie; Eugene Liu; Zhengming Du; Daniel LaSala; William Boyar; Paul Steed
Journal:  Bioorg Med Chem Lett       Date:  2007-01-25       Impact factor: 2.823

5.  Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer.

Authors:  Yoshiji Yamada; Nobuyuki Hamajima; Tomoyuki Kato; Hiroji Iwata; Yoshitaka Yamamura; Masayuki Shinoda; Motokazu Suyama; Tetsuya Mitsudomi; Kazuo Tajima; Suzuno Kusakabe; Hitoshi Yoshida; Yoshiko Banno; Yukihiro Akao; Masashi Tanaka; Yoshinori Nozawa
Journal:  J Mol Med (Berl)       Date:  2003-02-11       Impact factor: 4.599

6.  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.

Authors:  Robert Lavieri; Sarah A Scott; Jana A Lewis; Paige E Selvy; Michelle D Armstrong; H Alex Brown; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2009-03-06       Impact factor: 2.823

7.  Biochemical analysis of phospholipase D.

Authors:  H Alex Brown; Lee G Henage; Anita M Preininger; Yun Xiang; John H Exton
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

8.  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.

Authors:  Jana A Lewis; Sarah A Scott; Robert Lavieri; Jason R Buck; Paige E Selvy; Sydney L Stoops; Michelle D Armstrong; H Alex Brown; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2009-02-20       Impact factor: 2.823

9.  Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.

Authors:  Sarah A Scott; Paige E Selvy; Jason R Buck; Hyekyung P Cho; Tracy L Criswell; Ashley L Thomas; Michelle D Armstrong; Carlos L Arteaga; Craig W Lindsley; H Alex Brown
Journal:  Nat Chem Biol       Date:  2009-01-11       Impact factor: 15.040

Review 10.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

View more
  24 in total

1.  Tales from the war on error: the art and science of curating QSAR data.

Authors:  Marvin Waldman; Robert Fraczkiewicz; Robert D Clark
Journal:  J Comput Aided Mol Des       Date:  2015-08-20       Impact factor: 3.686

Review 2.  Drugs for allosteric sites on receptors.

Authors:  Cody J Wenthur; Patrick R Gentry; Thomas P Mathews; Craig W Lindsley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-02       Impact factor: 13.820

Review 3.  Chemical modulation of glycerolipid signaling and metabolic pathways.

Authors:  Sarah A Scott; Thomas P Mathews; Pavlina T Ivanova; Craig W Lindsley; H Alex Brown
Journal:  Biochim Biophys Acta       Date:  2014-01-15

Review 4.  Physiological and pathophysiological roles for phospholipase D.

Authors:  Rochelle K Nelson; Michael A Frohman
Journal:  J Lipid Res       Date:  2015-04-29       Impact factor: 5.922

Review 5.  Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis.

Authors:  Julian Gomez-Cambronero
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

Review 6.  Functional regulation of phospholipase D expression in cancer and inflammation.

Authors:  Dong Woo Kang; Kang-Yell Choi; Do Sik Min
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

Review 7.  Cellular and physiological roles for phospholipase D1 in cancer.

Authors:  Yi Zhang; Michael A Frohman
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

8.  Discovery of a highly selective PLD2 inhibitor (ML395): a new probe with improved physiochemical properties and broad-spectrum antiviral activity against influenza strains.

Authors:  Matthew C O'Reilly; Thomas H Oguin; Sarah A Scott; Paul G Thomas; Charles W Locuson; Ryan D Morrison; J Scott Daniels; H Alex Brown; Craig W Lindsley
Journal:  ChemMedChem       Date:  2014-09-10       Impact factor: 3.466

Review 9.  Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Authors:  Ronald C Bruntz; Craig W Lindsley; H Alex Brown
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

10.  Human PLD structures enable drug design and characterization of isoenzyme selectivity.

Authors:  Claire M Metrick; Emily A Peterson; Joseph C Santoro; Istvan J Enyedy; Paramasivam Murugan; TeYu Chen; Klaus Michelsen; Michael Cullivan; Kerri A Spilker; P Rajesh Kumar; Tricia L May-Dracka; Jayanth V Chodaparambil
Journal:  Nat Chem Biol       Date:  2020-02-10       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.